

C.75.New effective therapy, with low toxicity and low costs, implying new targets

Écrit par Dr. Adrien Caprani

Mercredi, 13 Juin 2012 23:47 - Mis à jour Mercredi, 07 Novembre 2012 17:31

C.75.New effective therapy, with low toxicity and low costs, implying new targets (D-Mannose receptor, sodium channel voltage dependant), and Resveratrol. Validation with the presentation of a clinical case.

A. Caprani

1

, G.M.K. Tran

1,2

, L. Roudière

3

Association 'POSITIFS', Paris Cedex, France(

positifpresident@yahoo.fr

),

Clermont-Ferrand University, Hospital Hotel-Dieu, Public Health, Clermont-Ferrand, France(

mkg_tran@yahoo.fr

),

3

Hôpital Pitié-Salpêtrière, Paris, France

Poster présenté au symposium international ISHEID 2012 Marseille- Abstract publié dans *Retrovirology* 2012 Vol 9 Suppl 1:P13

Background

Neglected data more or less recent, showed that the voltage-dependent sodium channel (Tran MKG, 13th ISHEID 2002, IXth Int. Conf. AIDS, Berlin 1993) and the Mannose receptor [Bandivdekar AH 14° ISHEID Toulon 2006 (PP 2.14); J Acquir. Immune. Defic. Syndr. 2008, Virology. 2008, J. Virol 2012(86-4) 2153; J Reprod Immunol. 2011(92(1-2)1; Science 2011(25 334(6059)1097; Neurobehav HIV Med 2011(1;3)41; PLoS One 2011, 6(11) e 28014] are involved in the transmission of HIV. In particular, the mannose Receptor seem essential for contamination since in a discordant couple, the uninfected male partner does not own this receptor (14° ISHEID, Bandivdekar A.H et al.). Resveratrol is a natural product which exhibits, in vitro, an antiviral activity against HIV-1. Its antiviral activity involves an anti TaT activity (Zhang HS, 2009) and a synergy with nucleoside analogues ((Heredia A, 2008)). From these facts, we decided to change the therapy of a 67 years old patient, HIV+ since 28 years, under active antiretroviral therapy for 14 years, and under the following therapy (Reyataz 200mg twice daily, Kivexa (Abacavir 600mg + Efavirenz 300mg) once daily) since 3 years. The patient presenting many side effects (coronary heart disease, osteoporosis, lipodystrophy, libido disorders, ...), we have, in order to reduce the long term toxicity of orthodoxic therapies, decided to replace successively his therapy by the following ones:

C.75.New effective therapy, with low toxicity and low costs, implying new targets

Écrit par Dr. Adrien Caprani

Mercredi, 13 Juin 2012 23:47 - Mis à jour Mercredi, 07 Novembre 2012 17:31

1)Eпивir(150mg twice daily)+Reyataz(200mg twice daily)+Resveratrol TR (500mg twice daily), during 6 months;2) Epивir(150mg twice daily) + Resveratrol TR (500mg twice daily), D-Mannose 1g thrice daily, Omacor(ethyl esters of omega3 fatty acids) 1g twice daily,during 10 months. We have to recall that omega-3 fatty acids bind the Na+ channel(Isbilan Banu 2006);3) Resveratrol TR (500mg twice daily), D-Mannose 1g thrice daily, Omacor(ethyl esters of omega3 fatty acids) 1g twice daily, during one month.

Methods

Measurements of viral load, CD4 and CD8 and other blood parameters were followed during 18 months every month or 6 weeks.

Results

Our results show that over a period of 16 months, the patient remains undetectable(viral load